Add to ORKG5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variety of cancers. Dihydropyrimidine dehydrogenase (DPD) catalyzes the first catabolic step of the 5-FU degradation pathway, converting 80% of 5-FU to its inactive metabolite. Approximately 0.3% of the population demonstrate complete DPD deficiency, translating to extreme toxicity of 5-FU. Here we present a case of a patient who had a fatal outcome after treatment with 5-FU who was found to have an unknown DPD deficiency discovered at autopsy
5-Fluorouracil (5-FU) is one of most frequently used chemotherapeutic medications for the treatment ...
Dihydropyrimidine dehydrogenase (DPD) is the initial enzyme acting in the catabolism of the widely u...
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the i...
5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variet...
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5...
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5...
The identification of genetic factors associated with either responsiveness or resistance to 5-fluor...
5-fluorouracil (5-FU) and its pro-drug capecitabine are widely used anticancer agents. Most 5-FU cat...
A 63-year-old Japanese male with stomach adenocarcinoma received oral 5-fluorouracil derivative, cis...
5-fluorouracil pharmacokinetics, dihydropyrimidine dehydrogenase-activity and DNA sequence analysis ...
5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usua...
Background: Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of the met...
Background: The fluoropyrimidine anticancer drug, especially 5- fluorouracil (5-FU) and its prodrug ...
5-Fluorouracil remains a foundational component of chemotherapy for solid tumour malignancies. While...
Introduction: Fluoropyrimidines such as 5-fluorouracil (5-FU) and its orally active prodrug, capecit...
5-Fluorouracil (5-FU) is one of most frequently used chemotherapeutic medications for the treatment ...
Dihydropyrimidine dehydrogenase (DPD) is the initial enzyme acting in the catabolism of the widely u...
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the i...
5-Fluorouracil (5-FU), in combination with other cytotoxic drugs, is commonly used to treat a variet...
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5...
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5...
The identification of genetic factors associated with either responsiveness or resistance to 5-fluor...
5-fluorouracil (5-FU) and its pro-drug capecitabine are widely used anticancer agents. Most 5-FU cat...
A 63-year-old Japanese male with stomach adenocarcinoma received oral 5-fluorouracil derivative, cis...
5-fluorouracil pharmacokinetics, dihydropyrimidine dehydrogenase-activity and DNA sequence analysis ...
5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usua...
Background: Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme of the met...
Background: The fluoropyrimidine anticancer drug, especially 5- fluorouracil (5-FU) and its prodrug ...
5-Fluorouracil remains a foundational component of chemotherapy for solid tumour malignancies. While...
Introduction: Fluoropyrimidines such as 5-fluorouracil (5-FU) and its orally active prodrug, capecit...
5-Fluorouracil (5-FU) is one of most frequently used chemotherapeutic medications for the treatment ...
Dihydropyrimidine dehydrogenase (DPD) is the initial enzyme acting in the catabolism of the widely u...
BACKGROUND: Dihydropyrimidine dehydrogenase (DPD) is a pyrimidine catabolic enzyme involved in the i...